步长制药：控股子公司与Helios、早安国际签署《经销、营销服务和代理协议》

Core Viewpoint - The company, Buchang Pharma, is expanding its market presence in Vietnam through a distribution agreement for its product Efparepoetin alfa, which is aimed at treating anemia in adult dialysis patients with chronic kidney disease [1] Company Summary - Buchang Pharma's subsidiary, Luzhou Buchang, plans to sign a distribution and marketing agreement with Helios and Aozan International in Vietnam [1] - Helios will act as the exclusive distributor in the region, while Aozan International will serve as an intermediary [1] - The product Efparepoetin alfa is specifically indicated for adult dialysis patients undergoing erythropoietin treatment due to anemia caused by chronic kidney disease [1] Financial Summary - In the third quarter of 2025, Buchang Pharma reported a net profit attributable to shareholders of 241 million yuan, representing a year-on-year increase of 195.44% [1]